ClinicalTrials.Veeva

Menu

Prognostic Value of Sarcopenia and Nutritional Status in Early-stage Non-small Cell Lung Cancer

Fudan University logo

Fudan University

Status

Completed

Conditions

Malnutrition
Non Small Cell Lung Cancer
Sarcopenia

Treatments

Radiation: CT scan
Device: Inbody 570
Device: JAMAR Dynamometer

Study type

Observational

Funder types

Other

Identifiers

Details and patient eligibility

About

Growing evidence has confirmed that the prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.

Full description

The prognosis of lung cancer is not only related to the stage of disease, but also to the physiological and psychological situation of the patients. Malignant tumors are often associated with weakness and cachexia, leading to less physical activities and worse moods. However, few studies that have attempted to investigate the impact of nutritional status on the prognosis of NSCLC. Existing applications of nutritional scoring systems in early-stage of NSCLC are very limited. Therefore, this study aims to observe the correlation between nutritional status and the prognosis of patients with early-stage NSCLC, to clarify the value in predicting the overall survival rate and progression-free survival rate of NSCLC patients, and to offer evidence for alleviating the social and economic burden of NSCLC.

Enrollment

469 patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • The patients with non-small cell lung cancer diagnosed by cytology or pathology meet the standards of clinical diagnosis and treatment guidelines for lung cancer of Chinese Medical Association (2018 Edition)
  • TNM staging diagnosis of lung cancer meets the stage IA-IIIA

Exclusion criteria

  • Severe heart failure, acute progressive pulmonary inflammation, acute liver and kidney dysfunction in recent 2 weeks
  • Incomplete clinical and follow-up data or disagreement or inability to conduct regular follow-up CT imaging evaluation
  • A history of other malignant tumors and related tumor chemotherapy within half year, and previous history of radiotherapy
  • Unable to walk, fail to complete the walking test, and the risk of fall down
  • Unable to complete BIA examination due to pacemaker implantation and other reasons
  • Withdraw from the study for any reasons

Trial design

469 participants in 2 patient groups

Early-stage NSCLC with sarcopenia
Description:
Patients diagnosed with NSCLC meeting Stage IA-IIIA as well as sarcopenia by the enrollment
Treatment:
Device: JAMAR Dynamometer
Device: Inbody 570
Radiation: CT scan
Early-stage NSCLC without sarcopenia
Description:
Patients diagnosed with NSCLC meeting Stage IA-IIIA but without sarcopenia by the enrollment
Treatment:
Device: JAMAR Dynamometer
Device: Inbody 570
Radiation: CT scan

Trial documents
1

Trial contacts and locations

1

Loading...

Central trial contact

Ting Zhao, MD; Ying-gang Zhu, MD, PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems